Zeffix lamivudine 3TC: Phase III and open label data; approved in some markets

BCHE and partner Glaxo Wellcome reported that 31 patients in Hong Kong receiving 100 mg daily lamivudine over

Read the full 180 word article

How to gain access

Continue reading with a
two-week free trial.